Regadenoson是一种A2A腺苷受体激动剂是一种冠状动脉血管扩张剂。
适应证：Lexiscan是一种药理学应激剂适用于在不能进行适当运动负荷患者中放射性核素心肌灌注显像(MPI)。
剂量和用法：Lexiscan推荐的剂量是5 mL (0.4 mg regadenoson)通过迅速静脉注射；随后立即用盐水和放射性药物冲洗。
禁忌证：有二级或三级AV阻滞，或窦房结功能失调患者不能给予Lexiscan除非患者 有功能良好的人工心脏起搏器
不良反应：对Lexiscan最常见(发生率 ≥ 5%)不良反应是呼吸困难、头痛、面红、胸部不适、眩晕、心绞痛、胸痛、和恶心。
药物相互作用：甲基黄嘌吟类，如，咖啡因和茶碱，可能干扰Lexiscan的活性。 氨茶碱可能用于减轻严重和/或对Lexiscan的持久不良反应。
[1]MIYAMOTO MI,VERNOTICO SL,MAJMUNDAR H,et al.Pharmacologic stress myocardial perfusion imaging:a practicalapproach[J].J Nucl Cardiol,2007,14(2):250-255.
[2]PRESS NJ,GESSI S,BOREA PA,et al.Therapeutic potentialof adenosine receptor antagonists and agonists[J].Expert OpinTher Pat,2007,17(8):979-991.
[3]SPICUZZA L,DI MARIA G,POLOSA R.Adenosine in theairways:implications and applications[J].Eur J Pharmcol,2006,533(1-3):77-88.
[4]CERQUEIRA MD.Advances in pharmacologic agents in imaging:new A2A receptor agonists[J].Curr Cardiol Rep,2006,8(2):119-122.
[5]JAROUDI WA,ISKANDRIAN AE.Regadenoson:a new myo-cardial stress agent[J].J Am Coll Cardiol,2009,54(13):1123-1130.
[6]ZHAO G,LINKE A,XU X,et al.Comparative profile ofvasodilation by CVT-3146,a novel A2A receptor agonist,andadenosine in conscious dogs[J].J Pharmacol Exp Ther,2003,307(1):182-189.
[7]TROCHU JN,ZHAO G,POST H,et al.Selective A2A adeno-sine receptor agonist as a coronary vasodilator in conscious dogs:potential for use in myocardial perfusion imaging[J].J CardiovascPharmacol,2003,41(1):132-139.
[8]HAGE FG,HEO J,FRANKS B,et al.Differences in heart rateresponse to adenosine and regadenoson in patients with andwithout diabetes mellitus[J].Am Heart J,2009,157(4):771-776.
[9]GAEMPERLI O,SCHEPIS T,KOEPFLI P,et al.Interaction ofcaffeine with regadenoson-induced hyperemic myocardial bloodflow as measured by positron emission tomography:arandomized,double-blind,placebo-controlled crossover trial[J].JAm Coll Cardiol,2008,51(3):328-329.
[10]ZHAO G,MESSINA E,XU X,et al.Caffeine attenuates theduration of coronary vasodilation and changes in hemodynamicsinduced by regadenoson(CVT-3146),a novel adenosine A2Areceptor agonist[J].J Cardiovasc Pharmacol,2007,49(6):369-375.
[11]LIEU HD,SHRYOCK JC,von MERING GO,et al.Regadenoson,a selective A2A adenosine receptor agonist,causes dose-dependent increases in coronary blood flow velocity in humans[J].J Nucl Cardiol,2007,14(4):514-520.
[12]HENDEL RC,BATEMAN TM,CERQUEIRA MD,et al.Initialclinical experience with regadenoson,a novel selective A2Aagonist for pharmacologic stress single-photon emission computedtomography myocardial perfusion imaging[J].J Am Coll Cardiol,2005,46(11):2069-2075.
[13]CERQUEIRA MD,NGUYEN P,STAEHR P,et al.ADVANCE-MPI Trial Investigators.Effects of age,gender,obesity,anddiabetes on the efficacy and safety of the selective A2A agonistregadenoson versus adenosine in myocardial perfusion imaging:integrated ADVANCE-MPI trial results[J].JACC CardiovascImaging,2008,1(3):307-316.
[14]ISKANDRIAN AE,GARCIA EV,FABER T.Analysis of serialimages:a challenge and an opportunity[J].J Nucl Cardiol,2008,15(1):23-26.
[15]LEAKER BR,O’CONNOR B,HANSEL TT,et al.Safety ofregadenoson,an adenosine A2A receptor agonist for myocardialperfusion imaging,in mild asthma and moderate asthmapatients:a randomized,double-blind,placebo-controlled trial[J].J Nucl Cardiol,2008,15(3):329-336.
[16]THOMAS GS,TAMMELIN BR,SCHIFFMAN GL,et al.Safetyof regadenoson,a selective adenosine A2A agonist,in patientswith chronic obstructive pulmonary disease:a randomized,double-blind,placebo-controlled trial(RegCOPD trial)[J].JNucl Cardiol,2008,15(3):319-328.
[17]Palle, V.P., et al.: J. A. Drug Dev. Res., 50, 64 (2000)。
[18]Gordi, T., et al.: J. Clin. Pharmacol., 47, 825 (2000)
[19]Zhao, G., et al.: J. Cardiovas. Pharmacol., 52, 467 (2000)
[20]Botvinick, E., et al.: J. Nuc. Med. Technol., 37, 14 (2000)
